Table 1 Main characteristics of included trials
Study | Country | No of pts | Age (RIPreC / control) | Type of heart disease | Timing of RIPreC | RIPreC site, duration (cycles × min) and pressure | Propofol use | Risk of bias |
|---|---|---|---|---|---|---|---|---|
Cheung 2006 [17] | Canada | 37 | 0.9 / 2.2 years | CHD | 5–10 min before CPB | LL, 4 × 5, 15 mmHg > SAP | No | Unclear |
Zhou 2010 [18] | China | 60 | 5.4 / 5.1 months | VSD | 24 h and 1 h before surgery | UL, 3 × 5, 240 mmHg | Unknown | Unclear |
Luo 2011[19] | China | 40 | 2.2 / 3.1 years | VSD | Immediately after anesthesia induction | LL, 3 × 5, 200 mmHg | No | Unclear |
Lee 2012 [20] | Korea | 55 | 3.7 / 3.4 months | VSD | ~ 10 min after anesthesia induction | LL, 4 × 5, 30 mmHg > SAP | No | Unclear |
Pavione 2012 [21] | Brazil | 22 | 5.8 / 6.1 months | CHD | 24 h before surgery | LL, 4 × 5, 15 mmHg > SAP | No | Unclear |
Pedersen 2012 [22] | Denmark | 105 | 1.0 / 0.9 years | CHD | Immediately after anesthesia induction | LL, 4 × 5, 40 mmHg > SAP | Yes | High |
Jones 2013 [23] | Australia | 39 | 8.1 / 5.5 days | TGA, HLHS | After anesthesia induction | LL, 4 × 5, 15 mmHg > SAP | No | Unclear |
Pepe 2013 [24] | Australia | 40 | 7.6 / 7.4 months | ToF | Immediately after anesthesia induction | LL, 4 × 5, 30 mmHg > SAP | No | Unclear |
McCrindle 2014 [25] | Canada | 299 | 2.2 / 3.1 years | CHD | During anesthesia induction | LL, 4 × 5, 15 mmHg > SAP | Yes | Unclear |
Guerra 2017 [26] | Canada | 45 | 7.5 / 13.7 days | CHD | 24–48 h before surgery and intra-operatively before CPB | LL, 4 × 5, 20 mmHg > SAP | No | Low |
Wu 2018 [27] | China | 112 | 10.5 / 11.2 months | ToF | After anesthesia, 55–65 min before CPB | LL, 3 × 5, 30 mmHg > SAP | No | Low |
Kang 2018 [28] | China | 449 | 3.3 / 2.6 years | CHD | 12 h before surgery | LL, 4 × 5, 30 mmHg > SAP | Unknown | High |
Rodriguez 2020 [29] | UK | 49 | 19 / 9 months | CHD | 15–20 h before surgery and after anaesthesia induction prior to surgery | UL or LL, 3 × 5, 20 mmHg > SAP | Unknown | Low |